Clinical trial NCT05490030: Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants
Official title: A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Control Participants
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Hepatic Impairment
Keywords: Hepatic
Impairment
TNO155
Phase 1
pharmacokinetics
safety
Tolerability
Child-Pug
Lead sponsor: Novartis
Sponsor class: INDUSTRY
Collaborators: name: Pharmaceutical Research Associates
First posted: 2022-08-05
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study will be divided into 2 parts. Participants in the hepatic impairment groups will be staged by their respective degree of hepatic impairment according to the Child Pugh classification score determined at the screening visit and confirmed unchanged at the baseline visit.

Healthy participants who were identified and enrolled as matching partners for a hepatic impairment group in Part I can serve as matching partners for participants in hepatic impairment group in Part II if they fulfilled the matching criteria. Otherwise, additional matched healthy participants will be enrolled.

Part I: will include participants with mild and moderate levels of hepatic impairment as well as healthy control participants assigned to the groups Part II: will include participants with severe hepatic impairment.
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate the effect of various degrees of hepatic impairment on plasma pharmacokinetics (PK), safety and tolerability of TNO155.

The results of this study will guide the Novartis recommendation regarding whether or not a dose adjustment may be needed when treating patients with hepatic impairment.

Detailed description: This is a study to evaluate the PK of TNO155 in participants with mild, moderate or severe hepatic impairment compared to matched healthy control participants with normal hepatic function.

The study will be divided into 2 parts. Participants in the hepatic impairment groups will be staged by their respective degree of hepatic impairment (mild, moderate, or severe) according to a classification score determined at the screening visit and confirmed unchanged at the baseline visit.

Each participant in the healthy control group may be matched to 1 or more evaluable participants with hepatic impairment with respect to age (± 10 years), body weight (± 20%), sex and smoking status (smoker vs. non smoker). Each participant in the control group can be matched to participants from any hepatic impairment group but cannot be matched to more than 1 participant from the same hepatic impairment group.

All participants will be domiciled from Day -1 until Day 11. All participants should have a poststudy safety follow-up contact conducted approximately 30 days after administration of study treatment. The study will be considered complete once all the participants have finished the required assessments, dropped out, or been lost to follow-up before completing the required assessments.

Eligibility criteria: Inclusion Criteria:

All participants Participants must weigh at least 50 kg and no more than 120 kg and must have a body mass index (BMI) within the range of 18.0 to 38.0 kg/m2, inclusive, for healthy participants. For participants with hepatic impairment without overt ascites, the BMI should be within the range of 18.0 to 40.0 kg/m2. For participants with hepatic impairment with overt ascites, the BMI should be within the range of 18.0 to 45.0 kg/m2.

Group 1

•Each healthy control participant must match in age (± 10 years), sex, body weight (± 20%), and smoking status to at least 1 hepatic impairment participant in Groups 2, 3 and/or 4.

Groups 2 to 4 •Participants with mild, moderate or severe hepatic impairment must have a Child-Pugh score clinically determined at screening and confirmed unchanged at baseline calculated as per the Child-Pugh classification in line with the hepatic impairment status of each Group

Exclusion Criteria:

All Participants

* Use of drugs (prescription, non-prescription and herbal remedies such as St John's wort) known to affect CYP3A or UGT1A3, including UGT1A3 inhibitors and inducers and strong and moderate CYP3A inhibitors and inducers, within 4 weeks prior to dosing until completion of the End of Study Visit.
* Acute or chronic hepatitis B or C infection or active infection requiring therapy that will not be completed before screening.

Left ventricular ejection fraction (LVEF) \< 50% or below the institutional standard lower limit, whichever is higher, as determined by multiple gated acquisition (MUGA) scan or Trans-thoracic echocardiography (TTE) at screening or baseline.

•At screening, history of retinal vein occlusion (RVO) or presence of predisposing factors to RVO or central serous retinopathy, or any other clinically significant ophthalmologic abnormalities determined by an ophthalmologist.

Group 1

* Any single parameter of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) exceeding 2.5 × upper limit of normal (ULN) or total bilirubin ≥ 1.5 ULN OR any elevation above ULN of more than 1 parameter of ALT, AST, GGT, ALP, or serum bilirubin at screening or baseline.
* Impaired renal function as indicated by clinically significantly abnormal creatinine or blood urea nitrogen and/or other urea values outside local laboratory ranges or abnormal urinary constituents at screening or baseline.

Groups 2 and 3

* Severe complications of liver disease within the preceding 3 months prior to dosing.
* Hospitalization due to liver disease within the preceding 1 month prior to dosing.
* Participant has received liver transplant at any time in the past and is on immunosuppressant therapy.
* Participants requiring paracentesis more than every 3 weeks for the management of ascites are excluded.

Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Area under the concentration-versus-time curve (AUC) from time zero to the last measurable plasma concentration (AUClast) of TNO155
timeFrame: Up to 240 hours post single dose
measure: AUC from time zero to time "t" (AUC0-t) of TNO155
timeFrame: Up to 240 hours post single dose
measure: AUC from time zero to infinity (AUCinf) of TNO155
timeFrame: Up to 240 hours post single dose
measure: Maximum (peak) observed plasma concentration (Cmax) of TNO155
timeFrame: Up to 240 hours post single dose
measure: Time to reach maximum observed plasma concentration (Tmax) of TNO155
timeFrame: Up to 240 hours post single dose
measure: Elimination half-life (T1/2) of TNO155
timeFrame: Up to 240 hours post single dose
measure: Sampling time of the last measurable plasma concentration (Tlast) of TNO155
timeFrame: Up to 240 hours post single dose
measure: Apparent plasma clearance (CL/F) of TNO155
timeFrame: Up to 240 hours post single dose
measure: Apparent volume of distribution during terminal phase (Vz/F) of TNO155
timeFrame: Up to 240 hours post single dose
Secondary outcomes:
measure: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: Up to 30 days post single dose
measure: Unbound Cmax (Cmax,u) of TNO155
timeFrame: Up to 240 hours post single dose
measure: Unbound AUClast (AUClast,u) of TNO155
timeFrame: Up to 240 hours post single dose
measure: Unbound AUCinf (AUCinf,u) of TNO155
timeFrame: Up to 240 hours post single dose
measure: Unbound CL/F (CL/F,u) of TNO155
timeFrame: Up to 240 hours post single dose
measure: Renal clearance (CLr) of TNO155
timeFrame: Up to 240 hours post single dose
measure: Apparent non-renal clearance (CLNR/F) of TNO155
timeFrame: Up to 240 hours post single dose
measure: Fraction of dose excreted in urine (fe) of TNO155
timeFrame: Up to 240 hours post single dose
Other outcomes:
Locations:
Study officials:
References: